Eli Lilly And Company (LLY): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Eli Lilly and Company ( LLY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.3%. By the end of trading, Eli Lilly and Company rose $0.85 (1.5%) to $56.72 on average volume. Throughout the day, 5,290,695 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5,159,000 shares. The stock ranged in a price between $55.92-$57.10 after having opened the day at $56.10 as compared to the previous trading day's close of $55.87. Other companies within the Drugs industry that increased today were: Apricus Biosciences ( APRI), up 19.1%, Insmed ( INSM), up 16.4%, Rosetta Genomics ( ROSG), up 15.7% and Optimer Pharmaceuticals ( OPTR), up 13.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $63.4 billion and is part of the health care sector. The company has a P/E ratio of 13.5, below the S&P 500 P/E ratio of 17.7. Shares are up 13.3% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 4 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Savient Pharmaceuticals ( SVNT), down 14.1%, China Pharma ( CPHI), down 11.5%, Genvec ( GNVC), down 9.8% and Questcor Pharmaceuticals ( QCOR), down 9.5% , were all laggards within the drugs industry with Regeneron Pharmaceuticals ( REGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

null

More from Markets

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Global Stocks Slip as 3% 10-Year Yields, Tech Weakness Unsettle Markets

Global Stocks Slip as 3% 10-Year Yields, Tech Weakness Unsettle Markets

Akorn Plunges as Germany's Fresenius Ditches Takeover Amid Data Allegations

Akorn Plunges as Germany's Fresenius Ditches Takeover Amid Data Allegations

Stocks Sputter as U.S. 10-Year Yields Test 3% Amid Commodity-Led Inflation Spike

Stocks Sputter as U.S. 10-Year Yields Test 3% Amid Commodity-Led Inflation Spike